Helping Your Research
Perform multiplex gene expression analysis in human or mouse with 770 genes from different immune cell types, common checkpoint inhibitors, CT antigens, and genes covering both the adaptive and innate immune response. The panel measures many features of the immune response to facilitate rapid development of clinical actionable gene expression profiles in the context of cancer immunotherapy.
- Comprehensive profiling of the immune response optimized for immuno-oncology research
- Identify tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment
- Assess mechanistic pathway activity for single or combination studies
- Customizable with up to 55 additional user-defined genes with Panel Plus option
The nCounter PanCancer Immune Profiling Panel is for cancer researchers that need more markers than is practical for RT-qPCR but don’t want the broad approach that next-gen sequencing (NGS) offers. The Panel is fully compatible with clinically relevant sample types such as fresh-frozen (FF) tissue, formalin-fixed, paraffin-embedded (FFPE) tumor sections, isolated immune cell populations such as PBMCs, and cell lysates. The panel may be used in conjunction with nCounter Panel Plus products for additional flexibility in experimental design.
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early recurrence and metastasis. Enoblituzumab is a humanized, Fc-engineered, B7-H3-targeting antibody that mediates antibody-dependent cellular cytotoxicity.
Digital spatial profiling of intraductal papillary mucinous neoplasms: Toward a molecular framework for risk stratification
The histopathologic heterogeneity of intraductal papillary mucinous neoplasms (IPMN) complicates the prediction of pancreatic ductal adenocarcinoma (PDAC) risk. Intratumoral regions of pancreaticobiliary (PB), intestinal (INT), and gastric foveolar (GF) epithelium may occur with either low-grade dysplasia (LGD) or high-grade dysplasia (HGD).
Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma
Glioblastoma (GBM) is the most aggressive brain tumor, with a median survival of ∼15 months. Targeted approaches have not been successful in this tumor type due to the large extent of intratumor heterogeneity.
Request a Quote
Contact our helpful experts and we’ll be in touch soon.